Sudeep Pharma announces a new order win

Total installed capacity would be 123,446 MT per annum, calculated as the existing 72,246 MT plus the 51,200 MT Nandesari addition ^[1]. This represents a derived capacity increase of approximately 70.88% over the existing base.

The expansion is broadly consistent with the reported utilization profile:

• Overall utilization: close to 50%, indicating substantial spare capacity across the existing platform ^[1].
• Pharma, food and nutrition: approximately 65%, against an indicated optimum of about 70% ^[1].
• Specialty ingredients: approximately 35–40% utilization, according to management commentary ^[2].

The implication is that the 51,200 MT facility is primarily a capacity-relief and product-mix expansion, rather than an addition being made after the entire existing network has reached full utilization. The pharma, food and nutrition business is relatively close to its optimal utilization level, while specialty ingredients have greater headroom. The new facility should therefore allow higher-value molecules and constrained product categories to scale without forcing additional volume through smaller, less efficient lines.

Important reconciliation point: the Annual Report materials also refer to total annual manufacturing capacity of 133,000 MT, including the upcoming greenfield facility ^[3]. That is 9,554 MT above the 123,446 MT arithmetic based on the reported 72,246 MT existing capacity. The supplied disclosures do not reconcile this difference; it may reflect a different capacity scope or inclusion of additional facilities, so 123,446 MT should be treated as the direct calculation from the stated existing base, while 133,000 MT is the Annual Report headline figure.

The exact Nandesari project capitalized cost cannot be confirmed because Sudeep Pharma did not separately disclose the project-level total. The closest reported figures are company-level FY26 capital work-in-progress of Rs 178.43 Crores and FY26 capex of Rs 118.15 Crores; neither is explicitly identified as the Nandesari project cost. ^{[4] [5]} Management commentary only stated that most Nandesari capex had been spent, with a further Rs 10–15 Crores expected by April 2026. ^[6]

Balance-sheet and coverage position

Analytical conclusion: The available post-expansion figures show a conservatively levered balance sheet and strong interest-servicing capacity. However, a true comparison with the pre-expansion financial position cannot be established because pre-expansion debt-to-equity and interest-coverage figures were not reported in the relevant disclosures. Therefore, it is not possible to quantify how much the Nandesari expenditure itself changed leverage or coverage. The data supports “expansion undertaken without evident balance-sheet stress,” but not a precise before-versus-after attribution.

The US allocation cannot be quantified from the filing. The approval was granted by the Gujarat Food and Drug Control Administration, not identified as a USFDA approval, and the facility announcement does not earmark any portion specifically for the US market ^[12].

The disclosed capacity split is by portfolio, not geography:

• 60% for the existing Pharma, Food & Nutrition portfolio: 30,720 MT, derived from 51,200 MT × 60% ^[12].
• 40% for newer categories: 20,480 MT, derived from 51,200 MT × 40% ^[12].

The filing says the facility will serve both domestic and international markets, but does not provide a US-specific allocation ^[12]. Commercial supplies are expected only in H2 FY27 after customer qualification, so the facility has not yet demonstrated a realized revenue-mix shift ^[12].

Revenue mix versus FY26: the change between domestic and regulated export revenue could not be confirmed. The cited material provides no comparable FY26 domestic/export revenue split and no post-approval revenue split. Therefore, it would be incorrect to translate the capacity allocation into a specific shift in revenue mix. At most, the approval expands the company’s ability to serve regulated international customers; the magnitude and timing of that export contribution remain dependent on customer qualifications and ramp-up.